|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||
REVIEWS AND ORIGINAL ARTICLES |
From the Department of Renal Medicine, Huddinge University Hospital, and Department of Neurology, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden.
Peripheral neuropathy during CAPD, was investigated in 27 nondiabetic
patients at the start of CAPD and after a mean of 24 months on CAPD with
measurements of nerve conduction velocity (NCV) and vibratory perception
threshold (VT). The clinical signs of neuropathy were quantified according to
a fixed protocol. During the study period, motor NCV decreased 7% in the
median nerve, and 9% in the peroneal nerve (p < 0.05); VT increased 45% in
the hand (p < 0.01), and 135% on the foot (p < 0.001); and the clinical
status improved in five and deteriorated in 14 patients (NS). We conclude (I)
that the neuropathy may deteriorate during CAPD, although it remains mild in
most instances, and (2) that the most characteristic finding is a markedly
impaired vibratory sensitivity.
KEY WORDS: Peripheral uremic neuropathy; nerve conduction velocity; vibration sense; middle molecules.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |